Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Zynerba Pharmaceuticals, Inc. ZYNE
$0.35
-$0.03 (-7.39%)
На 18:00, 12 мая 2023
+3 042.86%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
19851425.00000000
-
week52high
1.60
-
week52low
0.34
-
Revenue
0
-
P/E TTM
0
-
Beta
1.73079500
-
EPS
-0.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 11:00
Описание компании
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Canaccord Genuity | Buy | Buy | 23 июн 2022 г. |
| Needham | Hold | Buy | 01 июл 2020 г. |
| Cantor Fitzgerald | Overweight | Overweight | 28 мая 2020 г. |
| Needham | Buy | 21 окт 2019 г. | |
| Roth Capital | Buy | 30 апр 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Parker Albert P | D | 216790 | 5841 | 01 февр 2023 г. |
| ANIDO ARMANDO | D | 856946 | 11726 | 01 февр 2023 г. |
| Sebree Terri B | D | 537571 | 9321 | 01 февр 2023 г. |
| Fickenscher James E | D | 339882 | 5927 | 01 февр 2023 г. |
| Rosenberger Brian | D | 223989 | 4809 | 01 февр 2023 г. |
| Parker Albert P | A | 222631 | 17631 | 31 янв 2023 г. |
| ANIDO ARMANDO | A | 868672 | 42437 | 31 янв 2023 г. |
| Sebree Terri B | A | 546892 | 33688 | 31 янв 2023 г. |
| Fickenscher James E | A | 345809 | 21073 | 31 янв 2023 г. |
| Rosenberger Brian | A | 228798 | 13950 | 31 янв 2023 г. |
Новостная лента
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
GlobeNewsWire
07 мар 2023 г. в 07:00
DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 4:40 p.m. ET, and host investor meetings.
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
GlobeNewsWire
01 мар 2023 г. в 07:00
DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at Cowen's 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 2:50 p.m. ET, and host investor meetings. The conference is being held at the Boston Marriott Copley Place in Boston, Mass.
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
Zacks Investment Research
09 янв 2023 г. в 09:02
Want to try a different approach? Tap five stocks with increasing P/E ratios.
Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndrome
Proactive Investors
21 дек 2022 г. в 07:46
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolescents aged from three to 17 to treat symptoms of Fragile X syndrome (FXS). The pharma group said factors including the so-called 'Tripledemic' (high rates of respiratory syncytial virus (RSV), influenza and COVID-19) had led to higher-than-expected cancellations of initial screening visits at the trial's investigational centers, leading to slower-than-anticipated enrollment.
Zynerba Pharmaceuticals announces positive long-term data from Phase 2 INSPIRE trial at annual meeting of the American College of Neuropsychopharmacology
Proactive Investors
05 дек 2022 г. в 08:36
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Arizona. The poster, titled 'An Open-Label Tolerability and Efficacy Study of ZYN002 (cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE)', shows that through 38 weeks of treatment, statistically significant improvements were seen in children and adolescents treated with Zygel in the Pediatric Anxiety Rating Scale (PARS-R), all five scales of the Anxiety, Depression and Mood Scale (ADAMS), and all five subscales of the Aberrant Behavior Checklist – Community (ABC-C).